According to TipRanks.com, Goodman is a 1-star analyst with an average return of -1.9% and a 43.0% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Opthea Limited Sponsored ADR, and Amylyx Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axsome Therapeutics with a $87.71 average price target, a 190.6% upside from current levels. In a report issued on April 19, BTIG also maintained a Buy rating on the stock with a $62.00 price target.
Based on Axsome Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $33.98 million. In comparison, last year the company had a GAAP net loss of $29.16 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Read More on AXSM:
- Axalta Coating Systems (AXTA) Receives a Buy from Mizuho Securities
- Axalta Coating Systems (AXTA) Receives a Buy from Robert W. Baird
- Robert W. Baird Thinks PTC’s Stock is Going to Recover
- Zions Bancorporation National Association (ZION) Receives a Hold from Robert W. Baird
- Robert W. Baird Sticks to Its Buy Rating for O-I Glass (OI)